In Plain Tetms

Nad+ (short for nicotinamide adenine dinucleotide) is a natural substance your body makes and uses to help turn food into energy inside your cells. It also helps your cells repair damage and manage inflammation. Some healthcare providers offer Nad+ or related nutrients (like nicotinamide riboside) as a treatment to help support energy metabolism, heart health, blood vessel health, and other areas that researchers are still actively studying.

Nad+ can be given by mouth (as a capsule form of a related nutrient) or through an intravenous (IV) infusion into a vein, depending on what your provider has prescribed. Always follow the directions on your own prescription for how much to take, how often, and for how long — do not use a general schedule from somewhere else, since the right amount can vary from person to person.

Common side effects reported in studies include:

With IV Nad+: stomach upset, faster heartbeat, and chest pressure during the infusion, which usually goes away once the infusion is finished
With oral forms (related nutrients): mild tingling in the tongue, jaw, or arms, and mild cramping
Generally, studies have not found serious side effects with either oral or IV forms when used short-term

When to call your doctor: Contact your healthcare provider right away if you experience chest pain that does not go away, a very fast or irregular heartbeat, severe stomach pain, difficulty breathing, or any symptom that feels severe or worsens during or after your infusion or dose.

Important warnings:

Nad+ is not FDA-approved as a specific drug for any condition based on the information available; it is used as part of ongoing research and in some clinics as a compounded or supplement-based therapy.
Tell your provider about any allergies to niacin or nicotinamide-related products before starting treatment.
Tell your provider about all other medicines you take, including blood thinners, since interactions have not been fully studied.
If you are pregnant, breastfeeding, or considering pregnancy, or if you are giving this to a child, talk to your provider first, since safety in these situations has not been established in available research.
Do not change your dose or stop your treatment without talking to your healthcare provider first.

Overview

Nad+ (nicotinamide adenine dinucleotide) is an endogenous coenzyme and vitamin-derived cofactor that is central to cellular energy metabolism, redox reactions, and enzymatic signaling. It is available through commercial and compounding channels in oral and intravenous formulations, and is also studied in the form of its metabolic precursors (nicotinamide riboside, nicotinamide mononucleotide). Nad+ itself does not carry a specific FDA-approved drug indication in the sources reviewed; its clinical use is currently supported by dietary-supplement regulatory pathways for precursor compounds and by investigational clinical trials rather than an approved therapeutic label.

Background

Nad+ is a naturally occurring dinucleotide cofactor synthesized in the body from dietary tryptophan and vitamin B3-related precursors (nicotinic acid, nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide). Interest in Nad+ as a therapeutic target has grown from research showing that cellular NAD+ levels decline with age and are associated with metabolic, cardiovascular, and neurodegenerative disease processes. The sources reviewed do not establish FDA drug approval for Nad+ itself; rather, precursor compounds such as nicotinamide riboside have been evaluated under dietary supplement frameworks (including Generally Recognized as Safe status and New Dietary Ingredient Notifications) (S5), and multiple registered clinical trials are investigating NAD+-raising strategies across a range of conditions, including elevated systolic blood pressure and arterial stiffness (S1), heart failure and mechanical circulatory support (S2), Alzheimer's disease, Parkinson's disease, Huntington's disease, peripheral artery disease, and COVID-19-related renal protection, among others listed in the source documents. Intravenous Nad+ infusion is also used in commercial wellness and clinical settings, with a retrospective real-world tolerability study comparing it against intravenous nicotinamide riboside (S4). Overall, Nad+ occupies a position of substantial mechanistic interest and active clinical investigation, but its role in current evidence-based practice remains investigational for most indications discussed in the available sources.

Mechanism of action

Nad+ functions as an obligatory coenzyme for a broad set of oxidoreductase enzymes, cycling between its oxidized (Nad+) and reduced (NADH) forms to shuttle electrons in glycolysis, the citric acid cycle, and oxidative phosphorylation, thereby supporting mitochondrial ATP production. Beyond redox chemistry, Nad+ is consumed as a substrate by sirtuin deacetylases (including SIRT1) and by poly(ADP-ribose) polymerases, linking cellular Nad+ availability to epigenetic regulation, DNA repair, and inflammatory signaling. In preclinical work using the Nad+ precursor nicotinamide riboside, increased NAD+ availability was associated with upregulation of hepatic SIRT1 and PPARγ pathways and improved expression of tight- and adherens-junction proteins, suggesting downstream effects on metabolic gene regulation and epithelial barrier integrity (S3). In a human heart failure mechanistic study, the rationale for raising myocardial and blood NAD+/NADH levels was to improve mitochondrial function, alter protein and epigenetic modifications, and reduce inflammatory response, though this trial's design (rather than completed results) establishes the proposed mechanism (S2). Because endogenous Nad+ has limited direct cellular uptake compared with its precursors, most mechanistic and pharmacodynamic characterization in the sources reviewed comes from studies of precursor molecules that are converted intracellularly to Nad+.

How It Works

Absorption and BioavailabilityThe sources reviewed characterize pharmacokinetics primarily for the Nad+ precursor nicotinamide riboside rather than for Nad+ itself. Oral nicotinamide riboside chloride, administered across a dose-dependent range of doses, produced dose-dependent increases in whole blood Nad+ within two weeks of dosing, with increases sustained throughout an 8-week trial (S5). The specific dose levels used to generate these percentage increases are not established in the available sources (the source reports percentage increases in NAD+ associated with escalating doses, but the corresponding numeric dose values are not reliably extractable from the excerpt). This indicates that oral precursor supplementation can reliably elevate systemic Nad+ levels, but the absolute oral bioavailability of Nad+ itself is not established in the available sources.

DistributionNad+ is present in whole blood and myocardial tissue, as demonstrated by studies measuring blood and cardiac tissue NAD+/NADH levels following precursor supplementation (S2). Specific volume of distribution, plasma protein binding, and tissue-specific distribution parameters for Nad+ are not established in the available sources.

MetabolismNad+ is synthesized and interconverted via multiple pathways involving nicotinamide, nicotinic acid, nicotinamide riboside, and nicotinamide mononucleotide as precursors and intermediates. A rat model study of nicotinamide riboside supplementation demonstrated significant changes in serum NAD+, NADPH, nicotinamide, and nicotinic acid levels under conditions of chronic variable stress, indicating dynamic interconversion among these metabolites (S3). Detailed hepatic or enzymatic metabolic clearance pathways specific to exogenously administered Nad+ in humans are not established in the available sources.

Elimination and Half-LifeSpecific elimination half-life, route of excretion, and clearance values for Nad+ in humans are not established in the available sources.

Route-Specific Pharmacokinetic ConsiderationsIntravenous Nad+ infusion administered as 500 mg over four consecutive days produced measurably longer infusion times (averaging 97 minutes) compared with intravenous nicotinamide riboside at the same dose and schedule (averaging 37 minutes), attributed to differing tolerability profiles during infusion rather than to a stated pharmacokinetic mechanism (S4).

Drug-Drug InteractionsSpecific drug-drug interaction data for Nad+ are not established in the available sources. One heart failure trial protocol excluded participants with known allergies to niacin, nicotinamide, or warfarin, suggesting caution in the context of interconnected vitamin B3-pathway compounds and anticoagulant therapy, though no mechanistic interaction is described (S2).

Clinical evidence

Clinical evidence for Nad+ in the sources reviewed derives largely from trials of its precursor, nicotinamide riboside, and from limited direct comparative data on intravenous Nad+ administration.

Cardiovascular — Blood Pressure and Arterial StiffnessA randomized, double-blind, placebo-controlled phase IIa trial in middle-aged and older adults with elevated systolic blood pressure (120–139 mmHg) is evaluating 3 months of oral nicotinamide riboside supplementation versus placebo for systolic blood pressure and aortic stiffness (carotid-femoral pulse wave velocity), following a pilot study that reportedly showed an 8 mmHg reduction in systolic blood pressure over 6 weeks in this population compared with placebo (S1). The specific oral dose used in this trial is not established in the available sources. This larger trial's results are not reported in the available sources.

Heart FailureA randomized, placebo-controlled mechanistic trial administered oral nicotinamide riboside (or matching placebo) at a 2:1 randomization ratio to 40 participants undergoing elective left ventricular assist device implantation, with dose escalation to 1000 mg twice daily by day 3 and continued until the evening before surgery. The study aimed to measure myocardial and blood Nad+/NADH levels, mitochondrial function, and inflammatory markers in fresh cardiac tissue obtained at surgery (S2). Efficacy results are not reported in the available sources.

Stress-Related Metabolic and Hepatic Effects (Preclinical)In a rat model of chronic variable stress, nicotinamide riboside supplementation at three unspecified dose levels (mg/kg) corrected stress-induced elevations in glucose, corticosterone, ACTH, and insulin, restored NAD+, NADPH, nicotinamide, and nicotinic acid levels, upregulated hepatic PPARγ, SIRT1, GLUT2, IRS1, and FASN expression, and improved intestinal tight- and adherens-junction protein expression. The highest of the three tested doses most notably reduced markers of liver fibrosis and improved glucose metabolism and gut barrier integrity, though the specific mg/kg values are not established in the available sources (S3). This is an animal study; human translational data are not established in the available sources.

Tolerability Comparison — Intravenous Nad+ vs. Intravenous Nicotinamide RibosideA retrospective real-world tolerability study compared four consecutive days of 500 mg intravenous Nad+ against 500 mg intravenous nicotinamide riboside in a commercial setting, with 30-day follow-up. Intravenous Nad+ was associated with moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusion, resulting in a longer average infusion time (97 minutes) compared with intravenous nicotinamide riboside (37 minutes), which was associated with milder tingling and cramping. No significant changes occurred in ALT, AST, hsCRP, or BUN/creatinine in either group; alkaline phosphatase decreased significantly (within normal range) in the Nad+ group only, and HDL-C decreased significantly in the Nad+ group, while HbA1c decreased significantly in the nicotinamide riboside group. Neither group showed changes in fasting glucose or LDL-C (S4).

Long-Term Oral Precursor SafetyAn 8-week randomized, double-blind, placebo-controlled trial of oral nicotinamide riboside chloride, tested across a dose-dependent range, in healthy overweight adults found no flushing, no significant difference in adverse events versus placebo across doses, no elevation in LDL cholesterol, and no dysregulation of one-carbon metabolism, supporting a dose-dependent increase in whole blood Nad+ without associated adverse safety signals in this population. The specific dose values tested are not established in the available sources (S5).

Other Indications Under InvestigationRegistered clinical trials referenced in the source documents are investigating NAD+-raising strategies (chiefly via nicotinamide riboside) in Alzheimer's disease, Parkinson's disease, Huntington's disease, peripheral artery disease, skeletal muscle function in heart failure, cancer-therapy-related cardiac dysfunction, cognitive function/mood/sleep in older adults, COVID-19-related renal protection, and mitochondrial metabolism. Outcomes data from these trials are not reported in the available sources.

Safety & Side Effects

ContraindicationsSpecific absolute contraindications to Nad+ are not established in the available sources. One clinical trial protocol excluded participants with known allergies to niacin, nicotinamide, or warfarin as an eligibility criterion, which may be relevant given the shared metabolic pathway between Nad+ and vitamin B3-related compounds, though this represents a trial exclusion criterion rather than a formally established contraindication (S2).

Common Adverse Effects

Intravenous Nad+ infusion (500 mg over 4 consecutive days): moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusion, all reported to resolve upon completion of infusion (S4).
Intravenous nicotinamide riboside (comparator arm, same study, 500 mg over 4 consecutive days): minor tongue, jaw, and arm tingling, and mild cramping during infusion, also resolving upon completion (S4).
Oral nicotinamide riboside (dose-dependent range studied over 8 weeks): no flushing reported; no significant difference in adverse events compared with placebo across all doses tested (S5).
Oral β-nicotinamide mononucleotide (a related Nad+ precursor, 1250 mg once daily for up to 4 weeks): no severe adverse events observed; no changes exceeding physiological variation in anthropometric, hematologic, biochemical, urine, or body composition parameters (S6).

Serious Adverse EffectsNo serious adverse events were reported in the long-term oral nicotinamide riboside safety trial (S5) or the oral nicotinamide mononucleotide safety trial (S6). The intravenous Nad+ tolerability study reported infusion-related chest pressure and tachycardia that necessitated longer infusion times but did not describe these as serious adverse events requiring discontinuation (S4).

Monitoring ParametersBased on trial protocols and safety evaluations in the sources reviewed, monitoring parameters have included:

Liver enzymes: ALT, AST (no significant changes observed with intravenous Nad+ or nicotinamide riboside) (S4)
Inflammatory marker: hsCRP (no significant change) (S4)
Renal function: BUN/creatinine (no significant change) (S4)
Thyroid function: TSH (no significant change) (S4)
Lipid panel: HDL-C (significant decrease with intravenous Nad+), LDL-C (no change in either group) (S4)
Glycemic markers: HbA1c (significant decrease with intravenous nicotinamide riboside), fasting glucose (no change in either group) (S4)
Alkaline phosphatase: significant decrease with intravenous Nad+, remaining within normal reference range (S4)
Cardiac/vital sign monitoring: blood pressure and resting heart rate during and after infusion (S4)
Standard trial safety panels including anthropometry, hematology, biochemistry, urine analysis, and body composition (oral precursor studies) (S6)

Special Populations

Pregnancy: Safety and use in pregnancy are not established in the available sources.
Pediatric use: Safety and dosing in pediatric populations are not established in the available sources; reviewed trials enrolled adults (age greater than 18 years or specific ranges such as 50–79 years, 20–65 years).
Geriatric use: Multiple trials specifically enrolled middle-aged and older adults (50–79 years) for blood pressure and arterial stiffness outcomes, suggesting this population has been directly studied, though geriatric-specific dose adjustment is not established (S1).
Renal/hepatic impairment: Not established in the available sources as a specific dose-adjustment parameter for Nad+; severe renal disease and cirrhosis were used as exclusion criteria in one heart failure surgical trial context rather than as the basis for a graded dose adjustment (S2).